Adult Flu Vaccines 2020-2021
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- 75D30120D07110
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75D30120D07110 Federal IDV award
- Awardee
- Glaxosmithkline, LLC
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Atlanta GA 30341 USA
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention published a justification and approval for other than full and open competition to modify multiple indefinite delivery, indefinite quantity contracts held by GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, and Seqirus to purchase up to 50 million additional doses of inactivated influenza vaccine and live attenuated influenza vaccine for children and adults at $14.02 per dose, with a total value not to exceed $701 million. This increased procurement of influenza vaccines valued at up to $701 million is intended to support public health efforts to mitigate impacts on the healthcare system from COVID-19 by significantly expanding influenza vaccinations during the 2020-2021 influenza season under an unusual and compelling urgency as stipulated in FAR 6.302-2.
Notice text
CDC awarded the contracts listed below in December 2019 and January 2020 to support public sector routine annual influenza vaccinations for adults and children. This notices makes available a justification and approval for other than full and open competition (JOFOC) that applies to these contracts.
GLAXOSMITHKLINE LLC
Contract Numbers: 75D30120D07110, 75D30120D07111
ASTRAZENECA PHARMACEUTICALS LP
Contract Numbers: 75D30120D07112, 75D30120D07113
SANOFI PASTEUR INC.
Contract Numbers: 75D30120D07114, 75D30120D07115
SEQIRUS USA INC.
Contract Numbers: 75D30120D07116, 75D30120D07117
Under the authority of FAR 6.302-2, Unusual and compelling urgency, these contracts will be modified to support the purchase of additional inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) for children and adults in light of the current COVID-19 outbreak. Undertaking a campaign to significantly increase influenza vaccinations during the 2020/2021 influenza season is an additional step to help mitigate impacts on the healthcare system to allow focus on COVID-19.
The attached JOFOC is being made available within 30 days of the first modification made under its authority in accordance with FAR 6.305 and will remain active for 30 days.
The first contract modification related to this JOFOC was made on June 16, 2020. Additional contract modifications have and will continue to be made as necessary to support the purchase of additional vaccines up to the dollar value ceiling provided in the JOFOC.
Files
| File | Type | Posted |
|---|---|---|
| JOFOC.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Limited / Sole Source Justification | |
| Adult Flu Vaccines 2020-2021 | Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response | Office of the Assistant Secretary for Preparedness and Response | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity